Moderator
Indranil Bagchi, MS, PhD, GSK US, Collegeville, PA, United States
Speakers
Lotte Steuten, MSc, PhD, Office of Health Economics, London, United Kingdom; Darius Lakdawalla, PhD, University of Southern California, Los Angeles, CA, United States; Jens Grueger, PhD, Boston Consulting Group, Freiburg, Germany; Lizheng Shi, PhD, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States
To say that we currently live in a VUCA (Volatile, Uncertain, Chaotic, Ambiguous) world when it comes to trade and policy would be an understatement. Global biopharmaceutical innovation is entering a pivotal decade, driven in large part by sweeping U.S. policy reforms that extend far beyond domestic borders. Building off the first plenary on U.S. Most Favored Nation and Medicare Drug Price Negotiation policies, this plenary will focus on the implications outside of the US.
With constrained budgets, trade policy influencing cost effectiveness thresholds, and reference pricing shaping launch decisions, the “global access ecosystem” is undergoing significant disruption. Drawing on perspectives from global HEOR, payer policy, and industry experts, this session will address the following questions: What will be the impact on development decisions, evidence generation, pricing corridors, launch strategies, and long run incentives to invest in innovation?
The session will conclude with a forward-looking discussion on how health systems can sustain meaningful rewards for innovation and adaptations that are necessary for innovators and the evidence generation community to remain resilient amidst change.
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment